Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.…
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Sionna Therapeutics (NASDAQ: SION) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 2.825 USD on 20 November 2026, down 92.6% over 52 weeks. Its 52-week range is 2.760 USD to 54.97 USD: the price is 94.9% below the high and 2.4% above the low.
Its market capitalisation is 127.79M USD.
Sionna Therapeutics reports return on equity of -24.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 216.84M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 9 March 2027.